ZURICH, December 4, 2013 /PRNewswire/ --
Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced that Dr. Yamo Deniz is proposed to join Cytos' Board of Directors. Dr. Deniz played a key role in the filing and approval of multiple drugs and in-vivo diagnostics agents in several therapeutic areas of unmet need, including omalizumab (Xolair®) for the treatment of asthma in the US and the EU. His extensive experience in the clinical development of asthma products further strengthens Cytos' Board of Directors.
Dr. Christian Itin, Chairman and CEO of Cytos, said: "With Dr. Yamo Deniz we are strengthening our Board of Directors with an industry expert in allergic asthma, the key area of focus for our lead program CYT003. His experience in developing, obtaining approval for and commercialization of the first biological in asthma is highly relevant for the development and positioning of CYT003. Dr. Yamo Deniz will join as an independent director."
About Dr. Yamo Deniz
Yamo Deniz, MD, currently serves as Chief Medical Officer, Global Head of Medical & Pharmacovigilance at GE Healthcare Lifesciences. Prior to joining GEHC in 2010, Dr. Deniz held numerous senior clinical and leadership positions of increasing responsibilities in respiratory as well as inflammation groups at Genentech and Roche, respectively. Dr. Deniz played a key role in the filing and approval of multiple drugs and in-vivo diagnostics agents in several therapeutic areas of unmet need, including omalizumab (Xolair®) for the treatment of asthma in the US and the EU. He also oversaw the lifecycle management plans of marketed products for other indications. In addition, he led Genentech's Peanut Allergy program. Dr. Deniz graduated with a BA in Chemi
|SOURCE Cytos Biotechnology Ltd|
Copyright©2012 PR Newswire.
All rights reserved